Skip to content

About us

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. Our member companies are at the forefront of the global development and marketing of biosimilar medicines.

Biosimilars Canada provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocates for policies that support their timely approval, reimbursement, market acceptance and expanded use. Maximizing the use of biosimilar medicines provides a significant contribution to the sustainability of drug plans and healthcare systems while supporting positive patient outcomes.

In collaboration with its partners in the International Generic and Biosimilar Medicines Association (IGBA), Biosimilars Canada seeks to address global developments for the biosimilar medicines industry and participates in initiatives to raise the domestic and global awareness of biosimilar medicines such as Global Biosimilars Week. Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association.

Biosimilars Canada Board

Mike Woolcock, Apobiologix – Chair

Mike Casia, Organon – Vice Chair

Kamlesh Thakkar, Auropharma Inc.

Rosemarie (Rosie) Childerhose, Biocon Biologics

Martin Willner, Fresenius Kabi

Martin Arès, Pharmascience

Michel Robidoux, Sandoz

Barb Pimentel, Taro

Ben Gray, Teva

Michael Sine, Teva

Jim Keon, Biosimilars Canada (Ex-Officio)

Member companies

acic
apobiologix
auropharma
Baxter_logo
Biocon_Website
fresenius
Juno_Logo_350 px
Organon_Digital_FullColor_Logo
pharmascience
Biosimilars_Sandoz
sterimax-logo
taro-logo
teva